This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Bipap Automatic Servo Ventilation (autoSV) Advanced in Central Apnea Patients

This study has been completed.
Information provided by (Responsible Party):
Philips Respironics Identifier:
First received: September 9, 2010
Last updated: March 28, 2016
Last verified: March 2016
Results First Received: August 5, 2015  
Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Conditions: Cheyne-Stokes Respiration
Sleep Apnea, Central
Intervention: Device: BiPAP autoSV Advanced

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Twenty-nine patients were enrolled between September 2010 and February 2013. Two participants did not meet) criteria after centralized scoring of diagnostic and CPAP polysomnograms (PSGs) and were excluded from analysis. Twenty-seven participants (five women) completed 3 nights in-laboratory attended PSG, and 26 completed 3 months of follow-up.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
Diagnostic, Continuous Positive Airway Pressure (CPAP), ASV All participants first underwent a full night, attended diagnostic PSG. Eligible participants then had an attended full night Continuous Positive Airway Pressure (CPAP) manual titration followed by full night, attended, but automated titration with the BiPAP automatic Servo Ventilation.(AutoSV) Advanced™ (Philips Respironics, Murrysville, PA), device.

Participant Flow for 2 periods

Period 1:   Sleep Laboratory (3 Nights)
    Diagnostic, Continuous Positive Airway Pressure (CPAP), ASV
Didn't meet inclusion/exclusion criteria                2 

Period 2:   At Home (3 Months)
    Diagnostic, Continuous Positive Airway Pressure (CPAP), ASV
Lost to Follow-up                1 

  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
Diagnostic, Then CPAP, Then BiPAP autoSV Advanced Diagnostic, then CPAP, then BiPAP autoSV Advanced (within-subjects design)

Baseline Measures
   Diagnostic, Then CPAP, Then BiPAP autoSV Advanced 
Overall Participants Analyzed 
[Units: Participants]
[Units: Years]
Mean (Standard Deviation)
 59  (12) 
[Units: Participants]
Female   5 
Male   22 
Race/Ethnicity, Customized 
[Units: Participants]
African American   1 
Caucasian   25 
African American, Irish, Native American   1 
Region of Enrollment 
[Units: Participants]
United States   27 

  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Apnea/Hypopnea Index (AHI)   [ Time Frame: During a single night of polysomnography lasting up to 8 hours. ]

2.  Secondary:   Epworth Sleepiness Scale   [ Time Frame: 3 months ]

3.  Secondary:   Breathing Event Indexes   [ Time Frame: from the first 7 days of BiPAP autoSV Advanced at home treatment to the last 7 days of at home treatment ]

4.  Secondary:   Average Therapy Pressure Values   [ Time Frame: 3 months ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

Results Point of Contact:  
Name/Title: Dr. Shahrokh Javaheri
Organization: Bethesda North Hospital
phone: 513-793-7378

Publications automatically indexed to this study by Identifier (NCT Number):

Responsible Party: Philips Respironics Identifier: NCT01199042     History of Changes
Other Study ID Numbers: ST-1001-ASVWO-MS
Study First Received: September 9, 2010
Results First Received: August 5, 2015
Last Updated: March 28, 2016